Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Amgen's cancer drug combo cut death risk by 58% in lung cancer trial

Median survival reached 21.1 months with Imdelltra plus AstraZeneca's Imfinzi, versus 12.7 months for Imfinzi alone

Amgen's cancer drug combo cut death risk by 58% in lung cancer trial

We haven't written up this one. Quartz has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at qz.com →

More in Health & Medicine

More from Monday 26 October →